The FAS imposes a RUR 100,000 fine on the manufacturer of Miramistin


The Federal Antimonopoly Service (FAS) fined Infamed K, a manufacturer of antiseptics  d(Miramistin, Okomistin) for 100,000 rubles for inaccurate advertising; the corresponding resolution was published in the department’s database.

In January-February 2021, commercials for Miramistin were on air in Channel One, Rossiya 1, NTV, and TNT. The commercial ended with a packshot and the statement: “Miramistin is your safety rule number one,” and the drug in its package was shown.

According to the section “indications for use”, the drug is used for the complex treatment of acute and chronic otitis media, sinusitis, tonsillitis, laryngitis, pharyngitis; complex treatment of acute pharyngitis and/or exacerbation of chronic tonsillitis in children aged three to fourteen years. It follows from the advertising that Miramistin is a drug of first choice at the early symptoms of a cold.

“Accordingly, the advertising statement “Miramistin is your safety rule number one” expresses the advantage of Miramistin in comparison with other medicines that can be used to treat colds,” the FAS resolution states.

At the same time, it follows from the instructions for the use of Miramistin, firstly, that the drug is used only as part of the complex therapy of acute and chronic otitis, sinusitis, tonsillitis, laryngitis, pharyngitis, and secondly, it is not intended for the prevention of otolaryngological diseases.

The FAS concluded that the advertising contained false information about the advantages of Miramistin over other drugs used in the treatment of diseases, which is a violation of paragraph 1 part 3 of Article 5 of the law “On Advertising”.